Società Biocon Limited

BIOCON

INE376G01013

Biotecnologia

Consensus Analisti

Attività

Vendite per attività

Vendite per regione

Dirigenti

Amministratori

Classe di azioni

Azionisti

Partecipazioni

Coordinate società

Società del gruppo

Settore

Vendite per attività

Vendite per regione

Rating per Biocon Limited

Revisioni EPS

Utili trimestrali - Indice di sorpresa

Settore Farmaci bioterapeutici

Mercato chiuso - NSE India S.E. Altri mercati azionari 13:43:47 26/04/2024			Variaz. 5gg	Var. 1 gen.
306,4 ^INR	+5,06%		+17,10%	+22,73%

18/04	L'indiana Biocon sta sviluppando una propria versione di Wegovy, la sperimentazione clinica è probabile l'anno prossimo	RE
17/04	Biocon Limited firma un accordo esclusivo di licenza e fornitura con Biomm S.A.	CI

Biocon Limited è un'azienda biofarmaceutica con sede in India, che si concentra sul trattamento del diabete, del cancro e delle malattie autoimmuni. Il suo segmento comprende i Generici, i Biosimilari, i Nuovi Biologici e i Servizi di Ricerca. Ha sviluppato e commercializzato nuovi biologici, biosimilari e principi attivi farmaceutici (API) complessi a piccole molecole in India e in diversi mercati globali chiave, nonché formulazioni generiche negli Stati Uniti, in Europa e nei principali mercati emergenti. Il suo portafoglio di API include cardiologia, antidiabetici, immunosoppressori, sclerosi multipla, anticancro/oncologia e altri prodotti chiave. I suoi prodotti includono Tacrolimus, Rosuvastatina, Simvastatina, Atorvastatina, Pravastatina, Fingolimod e altri. Ha oltre cinque stabilimenti a Bangalore, Hyderabad e Visakhapatnam in India. I suoi impianti di produzione di API sfruttano piattaforme tecnologiche complesse che vanno dalla fermentazione microbica, alla purificazione cromatografica, alla sintesi chimica, alla sintesi peptidica e agli HPAPI.

Numero di dipendenti: 16 545

INR in Milioni	2022	Peso	2023	Peso	Delta
Biosimilars 49,8 %	34 301	41,9 %	55 599	49,8 %	+62,09%
Research 28,1 %	25 119	30,7 %	31 392	28,1 %	+24,97%
Generics 22,0 %	21 910	26,8 %	24 559	22,0 %	+12,09%
Novels 0,2 %	510	0,6 %	192	0,2 %	-62,35%

INR in Milioni	2022	Peso	2023	Peso	Delta
Rest of the World 37,4 %	21 468	26,2 %	41 791	37,4 %	+94,67%
United States 37,1 %	29 946	36,6 %	41 430	37,1 %	+38,35%
India 15,0 %	13 563	16,6 %	16 737	15,0 %	+23,40%
Ireland 10,5 %	16 863	20,6 %	11 784	10,5 %	-30,12%

Dirigenti	Titolo	Età	Da
Siddharth Mittal CEO	Chief Executive Officer	46	01/05/13
Peter Bains CEO	Chief Executive Officer	65	12/12/22
Kiran Mazumdar-Shaw CHM	Chairman	71	29/11/78
Manoj Kumar Pananchukunnath CTO	Chief Tech/Sci/R&D Officer	-	-
Mayank Verma CMP	Compliance Officer	-	01/01/12
Shreehas Tambe PRN	Corporate Officer/Principal	-	01/07/97
Paul Vazhayil Thomas PRN	Corporate Officer/Principal	-	-
Akhilesh Nand LAW	General Counsel	-	03/02/18
Amitava Saha HRO	Human Resources Officer	54	01/12/13

Amministratori	Titolo	Età	Da
Kiran Mazumdar-Shaw CHM	Chairman	71	29/11/78
Ravi Rasendra Mazumdar BRD	Director/Board Member	69	01/01/00
Bobby Kanubhai Parikh BRD	Director/Board Member	60	27/07/18
Damodaran Meleveetil BRD	Director/Board Member	76	27/04/16
Peter Bains CEO	Chief Executive Officer	65	12/12/22
Naina Lal Kidwai BRD	Director/Board Member	67	28/04/22
Eric Mazumdar BRD	Director/Board Member	31	01/11/21
Nicholas Haggar BRD	Director/Board Member	59	01/09/23
Siddharth Mittal CEO	Chief Executive Officer	46	01/05/13
Rekha Mehrotra Menon BRD	Director/Board Member	-	26/07/23

	Voto	Quantità	Flottante	Autocontrollo	Flottante totale
Azione A	1	1 196 804 982	446 383 305 ( 37,30 %)	0	37,30 %

Nome	Azioni	%	Valorizzazione
Kiran Mazumdar-Shaw 40,36 %	484 581 970	40,36 %	1 534 M ₹
John Shaw 19,76 %	237 211 164	19,76 %	751 M ₹
Life Insurance Corporation of India (Investment Portfolio) 4,413 %	52 984 653	4,413 %	168 M ₹
SBI Funds Management Ltd. 2,564 %	30 787 890	2,564 %	97 M ₹
Arohi Asset Management Pte Ltd. 1,579 %	18 951 731	1,579 %	60 M ₹
quant Money Managers Ltd. 1,236 %	14 841 313	1,236 %	47 M ₹
Arun Suresh Chandavarkar 1,099 %	13 200 000	1,099 %	42 M ₹
Mirae Asset Investment Managers (India) Pvt Ltd. 0,9991 %	11 995 545	0,9991 %	38 M ₹
Tata Asset Management Ltd. 0,6452 %	7 745 782	0,6452 %	25 M ₹
Ravi Rasendra Mazumdar 0,4416 %	5 301 321	0,4416 %	17 M ₹

Nome	Azioni	%	Valorizzazione
SYNGENE INTERNATIONAL LIMITED 54.52%	219 185 608	54.52%	1 844 100 578 $
EQUILLIUM, INC. 6.57%	2 316 134	6.57%	5 350 270 $

Biocon Ltd.

20th KM, Hosur Road Electronics City

560100, Bangalore

+91 80 2808 2808

http://www.biocon.com

Nome	Categoria e settore
SYNGENE INTERNATIONAL LIMITED	Miscellaneous Commercial Services
Biocon Research Ltd. Biocon Research Ltd. Pharmaceuticals: MajorHealth Technology Part of Biocon Ltd., Biocon Research Ltd. is an Indian company that develops and sells biotechnology products. The private company is based in Bangalore, India.	Pharmaceuticals: Major
Biocon Sdn. Bhd. Biocon Sdn. Bhd. Pharmaceuticals: MajorHealth Technology Biocon Sdn. Bhd. manufactures insulin products. It provides research and development activities of biopharmaceutical products. The company was founded in 2010 and is headquartered in Nusajaya, Malaysia.	Pharmaceuticals: Major
Biocon Biologics Ltd. (India) Biocon Biologics Ltd. (India) Pharmaceuticals: MajorHealth Technology Biocon Biologics India Ltd. operates as a biotech company. It develops treatments for chronicle diseases. The company is headquartered in Bengaluru, India.	Pharmaceuticals: Major
Biocon Pharma Ltd. Biocon Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Biocon Ltd., Biocon Pharma Ltd. is an Indian pharmaceutical company that manufactures pharmaceutical preparations. The private company is based in Bangalore, India.	Pharmaceuticals: Major
Biofusion Therapeutics Ltd. Biofusion Therapeutics Ltd. BiotechnologyHealth Technology Biofusion Therapeutics Ltd. is an Indian company that focuses on researching and developing new molecules for targeted immuno-oncology therapy. The private company is based in Bangalore, India.	Biotechnology
Biocon Biologics Uk Ltd. Biocon Biologics Uk Ltd. Miscellaneous Commercial ServicesCommercial Services Biocon Biologics UK Ltd. is a biopharmaceutical company founded in 2016. The private company is based in London, UK. The British company is focused on finding new and affordable ways to treat diabetes, cancer, and autoimmune diseases. Biocon develops affordable biosimilars, generic formulations, and complex APIs. The company's work in novel biologics and novel targets in large molecules has significant results in diabetes, oncology, and immunology. The company provides access to share information, news, press releases, company statements, media stories, factsheet, leadership profile, reports, video, and image gallery. Syngene, a division of Biocon, is divided into four divisions - drug discovery services, drug development services, manufacturing services, and dedicated R&D centers.	Miscellaneous Commercial Services
Syngene Scientific Solutions Ltd.

Rating Trading

Rating Investimento

ESG Refinitiv

A-

Altri rating

Vendita

Buy

Raccomandazione media

Hold

Numero di analisti

Ultimo prezzo di chiusura

306,4 INR

Prezzo obiettivo medio

279,1 INR

Differenza / Target Medio

-8,91%

Consenso

Revisioni delle Stime

Calendario della società

Biotecnologia/Farmaceutici

Biotecnologia e ricerca medica

Biotecnologia

Farmaci bioterapeutici

	Variaz. 1 gen.	Capi.
BIOCON LIMITED	+22,73%	4,39 Mrd
VERTEX PHARMACEUTICALS INCORPORATED	-2,31%	103 Mrd
REGENERON PHARMACEUTICALS, INC.	+0,56%	95,28 Mrd
ARGENX SE	+1,69%	22,15 Mrd
BIONTECH SE	-17,37%	21,02 Mrd
GENMAB A/S	-9,30%	18,15 Mrd
WUXI APPTEC CO., LTD.	-41,01%	16,74 Mrd
BEIGENE, LTD.	-14,85%	16,05 Mrd
NEUROCRINE BIOSCIENCES, INC.	+3,21%	13,68 Mrd
SAREPTA THERAPEUTICS, INC.	+33,54%	12,17 Mrd

Farmaci bioterapeutici